Table 2. Summary of Studies that Used HRQoL as Exposure (n = 5).
| Author | Year | Nation | Study Design | n | Mean Age (Median) | Time at Enroll | Severity | Child-Pugh Score | QoL Measurement | Number of QoL Assessments | Primary Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diouf et al. (56) | 2013 | France | Cohort | 271 | 67 | At diagnosis | Late-stage | A 182 | EORTC QLQ-C30 | 1 | OS |
| B 64 | |||||||||||
| C 2 | |||||||||||
| D 23 | |||||||||||
| Diouf et al. (58) | 2015 | France | Cohort | 271 | 67 | At diagnosis | Late-stage | A 182 | EORTC QLQ-C30 | 1 | OS |
| B 64 | |||||||||||
| C 2 | |||||||||||
| D 23 | |||||||||||
| Meier et al. (50) | 2015 | USA | Cohort | 130 | 57 | At diagnosis | All | A 56 | EORTC QLQ-C30, HCC18 | 1 | OS |
| B 45 | |||||||||||
| C 29 | |||||||||||
| Li et al. (57) | 2017 | Hong Kong | Cohort | 472 | (60) | After treatment | Hetero | A 319 | EORTC QLQ-C30, HCC18 | 1 | OS |
| B 130 | |||||||||||
| C 23 | |||||||||||
| Xing et al. (71) | 2018 | USA | Cohort | 30 | 62 | At diagnosis | Late-stage | A 20 | SF-36 | 4 | OS |
| B 10 |
OS = overall survival